![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
This editorial discusses several options to overcome statin intolerance in clinical practice. For example, switching to a different statin, changing statin dosing, using lipid-lowering drugs other than statins (e.g., ezetimibe, bile acid sequestrants and fibrates, alone or in combination), or combining statins with other lipid-lowering drugs. The authors focus on the potential mechanisms involved in statin-related myopathy. New lipid-lowering drugs currently in development (e.g., cholesterol ester transfer protein inhibitors [anacetrapib] and proprotein convertase subtilisin/kexin 9 inhibitors) inhibitors may help in the management of statin intolerance while achieving low-density lipoprotein cholesterol targets as set out by the guidelines.
Declaration of interest
This editorial was written independently. No company or institution supported it financially. DP Mikhailidis has given talks, attended conferences and participated in studies sponsored by Merck, Sharp & Dohme, and Genzyme. AP Agouridis is supported by a grant from the Hellenic Atherosclerosis Society. DR Nair has given talks, attended meetings and conferences, participated in clinical trials sponsored by Pfizer, MSD, Sanofi, Amgen and Abbott.